Sheldon L. Koenig - 13 Mar 2026 Form 4 Insider Report for Esperion Therapeutics, Inc. (ESPR)

Role
President and CEO, Director
Signature
/s/ Sheldon L. Koenig
Issuer symbol
ESPR
Transactions as of
13 Mar 2026
Net transactions value
$0
Form type
4
Filing time
16 Mar 2026, 16:20:30 UTC
Previous filing
18 Dec 2025
Next filing
18 Mar 2026
SEC
View on sec.gov

Reporting Owners (1)

Name Relationship Address Signature Signature date CIK
Koenig Sheldon L. President and CEO, Director C/O ESPERION THERAPEUTICS, INC., 3891 RANCHERO DRIVE, SUITE 150, ANN ARBOR /s/ Sheldon L. Koenig 16 Mar 2026 0001766524

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction ESPR Common Stock Award +723,760 +49% $0.000000* 2,198,277 13 Mar 2026 Direct F1, F2

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction ESPR Stock Option (right to buy) Award +647,460 $0.000000* 647,460 13 Mar 2026 Common Stock 647,460 $2.44 Direct F1
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 Such award will vest over a four (4) year period in equal quarterly installments, the first of which will be June 15, 2026.
F2 Includes 3,930 shares recently acquired in Esperion's Employee Stock Purchase Plan.